Back to Screener

Certara, Inc. Common Stock (CERT)

Price$6.12
Value ScoreC
Growth ScoreC
Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-43.45%
Price vs S&P 500 (4W)-10.80%
VGM Score46.51
Market Capitalization$905.39M

All Metrics

P/CF (Annual)9.40x
Book Value / Share (Quarterly)$6.63
P/TBV (Annual)2.28x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)7.67%
Cash Flow / Share (Quarterly)$0.41
Price vs S&P 500 (YTD)-44.87%
Gross Margin (TTM)61.59%
Net Profit Margin (TTM)-3.60%
EPS (TTM)$-0.10
10-Day Avg Trading Volume3.90M
EPS Excl Extra (TTM)$-0.10
Revenue Growth (5Y)11.46%
EPS (Annual)$-0.01
ROI (Annual)-0.12%
Gross Margin (Annual)61.53%
Net Profit Margin (5Y Avg)-3.88%
Cash / Share (Quarterly)$0.97
P/E Basic Excl Extra (TTM)103.67x
Revenue Growth QoQ (YoY)0.86%
ROA (Last FY)-0.10%
Revenue Growth TTM (YoY)6.40%
EBITD / Share (TTM)$0.42
ROE (5Y Avg)-1.30%
Operating Margin (TTM)2.17%
Cash Flow / Share (Annual)$0.44
P/B Ratio0.89x
P/B Ratio (Quarterly)0.86x
Net Income / Employee (Annual)$-1,100
EV / Revenue (TTM)2.50x
Net Interest Coverage (TTM)1.57x
ROA (TTM)-0.98%
EV / EBITDA (TTM)15.82x
EPS Incl Extra (Annual)$-0.01
Current Ratio (Annual)2.05x
Quick Ratio (Quarterly)1.80x
3-Month Avg Trading Volume3.62M
52-Week Price Return-48.95%
EV / Free Cash Flow (Annual)15.03x
P/E Incl Extra (TTM)103.67x
Revenue / Employee (TTM)$277,100
Tangible BV / Share (Quarterly)$3.81
P/S Ratio (Annual)2.16x
Asset Turnover (Annual)0.27x
52-Week High$13.88
Operating Margin (5Y Avg)1.50%
EPS Excl Extra (Annual)$-0.01
CapEx CAGR (5Y)27.31%
Tangible BV CAGR (5Y)7.65%
26-Week Price Return-27.52%
Quick Ratio (Annual)2.00x
13-Week Price Return-14.41%
Total Debt / Equity (Annual)0.28x
Current Ratio (Quarterly)1.88x
Enterprise Value$1.05B
Revenue / Share Growth (5Y)7.39%
Asset Turnover (TTM)0.27x
Book Value / Share Growth (5Y)4.45%
Revenue / Employee (Annual)$276,500
Pretax Margin (Annual)1.82%
Cash / Share (Annual)$1.19
3-Month Return Std Dev60.98%
Gross Margin (5Y Avg)60.62%
Net Income / Employee (TTM)$-10,000
EBITDA CAGR (5Y)38.00%
EBITDA Interim CAGR (5Y)-8.10%
ROE (Last FY)-0.15%
Net Interest Coverage (Annual)0.65x
EPS Basic Excl Extra (Annual)$-0.01
P/FCF (TTM)14.35x
Receivables Turnover (TTM)4.44x
EV / Free Cash Flow (TTM)16.61x
Total Debt / Equity (Quarterly)0.29x
EPS Incl Extra (TTM)$-0.10
Receivables Turnover (Annual)4.08x
ROI (TTM)-1.12%
P/S Ratio (TTM)2.16x
Pretax Margin (5Y Avg)-2.76%
Revenue / Share (Annual)$2.61
Tangible BV / Share (Annual)$3.87
Forward P/E14.73x
Free OCF CAGR (5Y)13.61%
Price vs S&P 500 (52W)-77.15%
P/E Ratio (TTM)103.67x
Year-to-Date Return-33.94%
5-Day Price Return11.07%
EPS Normalized (Annual)$-0.01
ROA (5Y Avg)-0.87%
Net Profit Margin (Annual)-0.38%
Month-to-Date Return-5.06%
Cash Flow / Share (TTM)$0.13
EBITD / Share (Annual)$0.48
Operating Margin (Annual)5.02%
LT Debt / Equity (Annual)0.27x
P/CF (TTM)9.99x
ROI (5Y Avg)-1.01%
P/E Excl Extra (TTM)103.67x
LT Debt / Equity (Quarterly)0.28x
EPS Basic Excl Extra (TTM)$-0.10
P/TBV (Quarterly)1.50x
P/B Ratio (Annual)1.32x
Pretax Margin (TTM)-1.16%
Book Value / Share (Annual)$6.68
Price vs S&P 500 (13W)-24.16%
Beta1.48x
P/FCF (Annual)12.98x
Revenue / Share (TTM)$2.66
ROE (TTM)-1.43%
52-Week Low$4.45
vGradeC
gGradeC
mGradeD
vgmGradeC
Show chart for

Earnings Surprise History

Q1 260.09est. 0.11

Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
3.85
3.80
3.80
3.75

Industry Peers — Software(265)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CERTCertara, Inc. Common Stock
CCD$6.12
MSFTMicrosoft CorpDBB$460.52
ORCLOracle CorpFCA$248.15
PLTRPalantir Technologies Inc. Class A Common StockFAB$160.65
SAPSAP SEDCD$196.11
CRWDCrowdStrike Holdings, Inc. Class A Common StockFBA$782.17
CRMSalesforce, Inc.CBC$209.60
SHOPShopify Inc. Class A subordinate voting sharesFBB$124.12
NOWSERVICENOW, INC.FBC$135.86
ADBEAdobe Inc.CCC$274.03
CDNSCadence Design SystemsFCB$414.16

About

Certara provides biosimulation and regulatory science software that accelerates drug development and market approval. Its modeling, simulation, and assessment solutions help pharmaceutical clients reduce clinical trial costs and timelines while enabling faster regulatory approval. The company operates globally with significant presence across the Americas, EMEA, and Asia Pacific regions.